The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | What to look for in novel CLL therapies
Kostas Stamatopoulos, MD, PhD from the Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece, discusses what is important when evaluating new therapies. Duration of response to treatment and patient quality of life are two major factors when considering new therapies and managing disease. This interview was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
